WASOG E-Learning: Sarcoidosis treatment

Sarcoidosis treatment, a case history

Questions following each of the presentations of professor Baughman (Watch video's at WASOG.ORG)

Aims of this on line course:
By means of following web lectures and the presented case study, reading recommended papers, and completing this test module (survey), you will learn:

1. the various options how to treat sarcoidosis
2. alternatives for corticosteroid treatment
3. how to deal with side effects
4. how to deal with dilemma’s in daily clinical practice

If you are a WASOG member you can apply for a Certificate of completion of this E Learning module at wasogme@wasog.org

This certificate you can use to apply for accreditation by a national scientific society of your own choice.
Workload: approximately 2-3 hours

Success,

WASOG

Question Title

* 1. Please enter your name and e-mail address

Name

E-mail address

WASOG member? yes/no

Question Title

* 2. Would you treat this patient?

yes, because he has lung involvement

yes, because he has skin disease

no, because he is not short of breath

no, because his skin lesions are not on his face

I would let the patient decide

Question Title

* 3. Which systemic therapy would you initiate, after no response to initial therapy?

none

prednisone

hydroxychloroquine

methotrexate

infliximab

Question Title

* 4. Which systemic therapy would you initiate now, after development of pulmonary symptoms?

stop all therapy

prednisone

stay with hydroxychloroquine

methotrexate

infliximab

Question Title

* 5. What would you do now, after worsening pulmonary symptoms?

add prednisone to methotrexate

switch from methotrexate to leflunomide

stop methotrexate and initiate infliximab

Question Title

* 6. In use of MTX in sarcoidosis, which statement is correct?

MTX is not useful as anti-inflammatory agent due to major toxicity

MTX is not appropriate for long-term use

MTX p.o. is as effective as s.c.

renal disease is not a contraindication for prescription of MTX

MTX should not be used: by men or women for 3 months before planned pregnancy

Question Title

* 7. In regard of discontinuation of TNF-α inhibitors in sarcoidosis, which statement is correct?

in case of severe uncontrolled side-effects

in case of primary ineffectiveness during 3-6 months treatment

in case of secondary ineffectiveness due to antibody formation

in case of stable disease during treatment with TNF-α inhibitors for at least 6-12 months

all of these above

Question Title

* 1. Please enter your name and e-mail address

Question Title

* 2. Would you treat this patient?

Question Title

* 3. Which systemic therapy would you initiate, after no response to initial therapy?

Question Title

* 4. Which systemic therapy would you initiate now, after development of pulmonary symptoms?

Question Title

* 5. What would you do now, after worsening pulmonary symptoms?

Question Title

* 6. In use of MTX in sarcoidosis, which statement is correct?

Question Title

* 7. In regard of discontinuation of TNF-α inhibitors in sarcoidosis, which statement is correct?

Question Title

* 8. Via this link you get to the PDF with explanation of the case.